Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older who have been diagnosed with nerve damage caused by chemotherapy (called CIPN) that has lasted more than six months after chemotherapy ended
- People who have lower leg or foot pain rated at 5 or higher on a scale of 0–10
- People who have already tried at least two medications for nerve pain without enough relief
- People who have had nerve testing that shows a specific pattern of nerve damage in the legs
- People who completed a trial (temporary) use of a 10-kHz spinal cord stimulator for CIPN and reported at least 75% reduction in pain during that trial
- People whose nerve condition is currently stable and not getting worse
- People who are on a consistent, unchanged pain medication routine
- People who are considered medically suitable for the surgical procedures this study involves
- People who can read and understand English questionnaires and sign a consent form in English
- People who are willing and able to give informed consent
- People who are willing and able to attend all required study visits and complete all study-related tasks
Who may not be able to join:
- People who do not wish to take part in the study
- People who have nerve damage in only one specific nerve in the lower leg (rather than a wider pattern of nerve damage)
- People who have had a lower limb amputation or leg ulcers
- People who have another painful condition unrelated to their chemotherapy-related nerve damage that is not being treated in this study
- People with a Body Mass Index (BMI) of 40 or above (a measure of body weight relative to height)
- People taking more than 120 mg of the medication omeprazole (confirm with trial site)
- People with a progressive nerve or neurological disease, such as multiple sclerosis, certain inflammatory nerve conditions, brain or spinal cord tumours, or severe spinal narrowing, among others
- People with certain serious health conditions, including bleeding or clotting disorders, or significantly reduced heart or lung function
- People who are receiving or planning to receive another non-SCS procedure to treat their leg pain during the study
- People who have active, spreading cancer or untreated localised cancer — only people whose cancer is considered to be in remission by their oncologist are eligible
- People with a life expectancy of less than one year
- People with untreated addiction or dependency on medications, alcohol, or illicit drugs
- People with an active, disruptive, or unstable psychological or psychiatric condition
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ryan S. D'Souza, MD, Mayo Clinic in Rochester
Phone: 855-776-0015
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Pain intensity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.